Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
United States Natural Gas
UNG
Invesco Solar ETF
TAN
4
The Technology Select Sector SPDR® Fund
XLK
5
The Health Care Select Sector SPDR® Fund
XLV
US Stock MarketDetailed Quotes
Prelude Therapeutics (PRLD)
- 3.810
- -0.270-6.62%
Close Jun 5 16:00 ET
- 3.830
- +0.020+0.52%
Post 16:18 ET
303.45MMarket Cap-3.81P/E (TTM)
4.060High3.742Low220.94KVolume4.050Open4.080Prev Close844.07KTurnover2.74%Turnover RatioLossP/E (Static)79.65MShares5.54052wk High5.04P/B30.70MFloat Cap0.75052wk Low--Dividend TTM8.06MShs Float95.375Historical High--Div Yield TTM7.80%Range %0.610Historical Low3.820Avg Price1Lot Size
PRLD Stock Chart
After-Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
PRLD Orderflow
Unit: --
PRLD Orderflow Trend
IntradayDayWeekMonth
No Data
Prelude Therapeutics (PRLD) News
Prelude Therapeutics Initiated With Early-Stage Biotech at Goldman Sachs
Prelude Therapeutics Launches Phase 1 Trial and Extends Runway
Prelude Therapeutics Reports Q1 EPS (13c), Consensus (27c)
Express News | Prelude Therapeutics Q1 EPS $(0.13) Beats $(0.25) Estimate, Sales $4.580M
$PRLD ($PRLD) Releases Q1 2026 Earnings
Prelude Therapeutics | 10-Q: Quarterly report
Prelude Therapeutics (PRLD) Stock Forum
$Prelude Therapeutics (PRLD.US)$ Prelude Therapeutics Presents Preclinical Data From Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
GlobeNewswire
Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer
Prelude Remains on Track to File I...
GlobeNewswire
Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer
Prelude Remains on Track to File I...
3
$Prelude Therapeutics (PRLD.US)$ looking forward to a big green candle tomorrow
1
$Prelude Therapeutics (PRLD.US)$ Reuters
1m
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (Ind) for PRT12396, a Mutant-Selective Jak2V617F Inhibitor
1m
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (Ind) for PRT12396, a Mutant-Selective Jak2V617F Inhibitor
3
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)